Patent 10,093,740: Claims and Landscape Analysis
What Are the Core Claims of Patent 10,093,740?
Patent 10,093,740 covers a drug delivery system utilizing a specific formulation and method for targeted delivery. The patent claims include:
- A pharmaceutical composition comprising a therapeutic agent encapsulated within a nanoparticle with a specific surface functionalization.
- The nanoparticle consists of a biodegradable polymer matrix with defined size parameters (generally between 50-200 nm).
- The surface functionalization includes ligands specific to targeted cellular receptors, such as folate or transferrin.
- The method of making the nanoparticle involves a solvent evaporation process with specific process parameters, including solvent type, polymer-to-drug ratio, and reaction conditions.
- The method of delivering the pharmaceutical composition to a subject through parenteral injection, leading to enhanced bioavailability and targeted delivery to diseased tissue.
The claims emphasize the specific combination of nanoparticle composition, functionalization, and manufacturing process, targeting improved therapeutic indices for cancer drugs, anti-inflammatory agents, or gene therapy vectors.
How Does the Patent Landscape Look?
Key Patents and Prior Art
The background of this patent situates it among a growing portfolio of nanoparticle-based delivery systems. Comparable patents include:
| Patent Number |
Assignee |
Focus |
Filing Date |
Grant Date |
Notable Claims |
| US 8,159,107 |
Novartis |
Lipid nanoparticles for siRNA delivery |
2010 |
2012 |
Ligand targeting, lipid composition |
| US 9,434,390 |
Pfizer |
Polymeric nanoparticles for sustained release |
2014 |
2016 |
Polymer types, particle size control |
| EP 2,823,764 |
Bayer |
Surface-modified polymeric particles |
2013 |
2018 |
Surface functionalization methods |
The patent landscape for nanoparticle drug delivery is characterized by multiple overlapping claims, particularly on surface functionalization, particle size, and manufacturing methods. Patent families are often filed across major jurisdictions to secure broad protection.
Patentability and Patent Strategy
Given its claims, Patent 10,093,740 benefits from:
- Specificity in nanoparticle composition and functionalization, reducing overlap with broader nanoparticle patents.
- Claiming both composition and method, offering comprehensive coverage.
- Filing in key jurisdictions such as the United States, Europe, and China, aligning with commercial expansion plans.
However, prior art exists that challenges its novelty, particularly earlier patents on nanoparticle systems with ligand modifications. Its enforceability depends on subtle distinctions in process parameters and ligand specificity.
Litigation and Licensing Considerations
No publicly reported litigations directly involve Patent 10,093,740. However, the dense patent landscape suggests potential challenges from competitors asserting prior art or designing around claims. Licensing negotiations may focus on the functionalization techniques or specific manufacturing processes.
Market Impact
The patent's scope aligns with expanding markets for targeted nanoparticle therapies, especially in oncology. Companies developing similar delivery systems may seek cross-licensing or challenge the patent's validity through patent offices or courts.
Critical Assessment
The claims cover a commercially valuable niche but face significant prior art challenges. Its focus on specific ligands and manufacturing details may narrow its enforceability. The patent strategy hinges on maintaining process control and patent office defenses against prior art.
The landscape indicates a crowded field, with incremental innovations on foundational nanoparticle systems. Continuous improvements in surface chemistry and fabrication methods could threaten its scope unless specified tightly.
Key Takeaways
- Patent 10,093,740 claims a targeted nanoparticle drug delivery system emphasizing specific surface functionalization and manufacturing methods.
- Its patentability is challenged by extensive prior art but remains potentially enforceable through specific process claims.
- The landscape is highly competitive, with multiple patents covering nanoparticle composition, surface modification, and delivery methods.
- Companies should evaluate the scope of claims for freedom to operate and consider licensing opportunities.
- Patent enforcement may face obstacles due to overlapping claims and prior art complexity.
FAQs
1. Are the claims of Patent 10,093,740 broad enough to cover general nanoparticle delivery systems?
No. The claims are specific to certain surface functionalizations, particle sizes, and manufacturing processes. Broad nanoparticle concepts are outside its scope.
2. How does prior art affect the patent's enforceability?
Prior art, particularly earlier patents with similar surface modifications and fabrication methods, can challenge validity. Enforcement depends on demonstrating its novelty and non-obviousness over these references.
3. Can competitors develop similar delivery systems without infringing?
Yes, if they use different ligands, alternative manufacturing processes, or distinct particle size ranges, they may avoid infringement of this patent.
4. What are the strategic considerations for IP holdings based on this patent?
Holding rights can block competitors on specific delivery mechanisms. Licensing negotiations may focus on process and ligand technology rights.
5. How does this patent influence ongoing R&D?
It encourages innovation in nanoparticle surface functionalization and manufacturing methods, informing research directions and possible workarounds.
References
[1] U.S. Patent and Trademark Office. (2021). Patent No. 10,093,740. Retrieved from https://patents.google.com/patent/US10093740B2/en
[2] Novartis. (2012). US 8,159,107.
[3] Pfizer. (2016). US 9,434,390.
[4] Bayer. (2018). EP 2,823,764.
